Susan Hasty, Publisher
Table of Contents . . . July 17th, 2002
Non-Subscriber - Summaries OnlyRelated Areas: Other Issues in Vaccine Weekly | Other Publications
Vaccination - Influenza vaccination reduces risk of adverse cardiac events during flu season
Vaccine Development - Conjugated CD20 vaccine elicits specific, polyclonal immune response in mice
Hepatitis B Vaccine - Waiting to vaccinate against hepatitis B may be best policy for preterm infants
Vaccine Development - Novel Leishmania donovani protein potential vaccine antigen
Vaccine Development - Proteomic methods promising for antigen identification
Vaccine Development - Therapeutic HPV vaccine shows promise
AIDS Prevention - Large-scale testing of new AIDS vaccine postponed
AIDS Vaccine - Study shows promising results for development of preventive vaccine
AIDS and HIV Vaccine - Antibody-resistant infection poorly controlled after DNA prime/boost regimens
Cancer Vaccines - Avax Technologies publishes data on antimetastatic activity of its vaccine in an animal tumor model
Diabetes - Additional phase I/II results show continued safety of NBI-6024 in adolescents
Drug Development - Trial results of antinicotine vaccine and gene therapy cancer product promising
HIV Therapy - Epimmune receives FDA clearance to initiate phase I/II therapeutic vaccine trial
Intellectual Property - Patent issued for innovative nanoparticle
Measles - Canada helps U.N. Children's Fund jumpstart vaccination campaign in Angola
Patents - Synergy Vaccines announces issuance of U.S. patent for SynerVax technology
Polio - World Health Organization declares European zone free of polio
Smallpox - Panel votes against nationwide inoculation
Trademark Granted - Protein Sciences announces granting of trademarks for GeneXpress and expresSF+
Vaccine Availability - Aventis Pasteur official tells Senate committee that vaccine shortages are preventable
Vaccine Development - Human testing of novel vaccine to fight nicotine addiction begins
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.